Register

Course Director & Faculty

Alpesh Amin, MD, MBA, MACP, SFHM
Co-Chair and Presenter
Alpesh Amin, MD, MBA, MACP, SFHM
University of California, Irvine
Irvine, California
Mark H. Drazner, MD, MSc
Co-Chair and Presenter
Mark H. Drazner, MD, MSc
University of Texas
Southwestern Medical Center
Dallas, Texas

Location

Mandalay Bay Convention Center
Room: Breakers ABGH
South Convention Center, Level 2
3950 Las Vegas Blvd. South
Las Vegas, NV 89119

Agenda

7:00 PM: Registration and Dinner

7:30 PM: Welcome and Introduction (Alpesh Amin, MD, MBA, MACP, SFHM)

7:40 PM: Rehospitalization for Heart Failure: What Do Hospitalists Need to Know? (Alpesh Amin, MD, MBA, MACP, SFHM)

7:55 PM: How Will New Heart Failure Treatment Guidelines Impact Current Practice? (Mark H. Drazner, MD, MSc)

8:25 PM: What Is on the Horizon: New and Emerging Therapy in Acute and Chronic Heart Failure? (Mark H. Drazner, MD, MSc)

8:55 PM: How Can Hospitalists Improve Coordination of Care? (Alpesh Amin, MD, MBA, MACP, SFHM)

9:20 PM: Q&A and Concluding Remarks (Alpesh Amin, MD, MBA, MACP, SFHM)

CME Information

Activity Description & Educational Objectives

Hospitalists play a vital role in the management of chronic heart failure (CHF) and should be able to monitor and assess disease symptoms, act as a member of a multidisciplinary care team, and help manage a patient’s therapeutic journey in the inpatient setting. Management of patients with CHF should be informed by an awareness of current treatment recommendations and best practices, as well as the use of novel treatment options in conjunction with long-standing strategies to help address uncontrolled or potentially debilitating symptoms.

Upon completion of this activity, participants should be better able to:

Target Audience

This activity has been designed to meet the educational needs of hospitalists, general internists, general practice/family practice physicians, and other clinicians involved in the management of CHF.

Requirements for Successful Completion

In order to receive credit, participants must attend the live activity and complete the request for credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon completion of the request for credit at the end of the post-test.

Media: Symposium
Release and Expiration Date: May 2, 2017
Time to Complete: 120 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity for any amount during the past 12 months.

Co-Chair and Presenter

Alpesh Amin, MD, MBA, MACP, SFHM
Thomas and Mary Cesario Endowed Chair, Department of Medicine
Professor of Medicine, Business, Public Health,
Nursing Science, & Biomedical Engineering
Executive Director, Hospitalist Program
University of California, Irvine
Irvine, California

Co-Chair and Presenter

Mark H. Drazner, MD, MSc
Clinical Chief of Cardiology
Medical Director, CHF/VAD/Transplant
University of Texas Southwestern Medical Center
Dallas, Texas

Medical Director

Chris Washburn, PhD
PVI, PeerView Institute for Medical Education

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by educational grants from Novartis Pharmaceuticals Corporation and ZS Pharma, Inc., a member of the AstraZeneca Group.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.